XELOX for Metastatic Breast Cancer

Completed · Phase 2

Conditions studied: Metastatic Breast Cancer

In brief

Both capecitabine and oxaliplatin have single agent activity in breast cancer. The combination has improved activity in other solid tumors. This study seeks to assess the activity of the combination in breast cancer.

Key facts

Study ID

NCT00204776

Run by

University of Wisconsin, Madison

People needed

37

Starts

2005-03-01

Expected to finish

2006-11-01

Last updated by the study team

2019-12-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• preserved organ function
• good performance status
• no more than one prior therapy
• no active brain metastasis

You may not qualify if…

• No prior capecitabine or oxaliplatin
• no con-current therapy

Where it is running

• University of Wisconsin — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.